Riskpilot← Back to searchSign inGet full accessBromma neurofys AB
ABActiveOrg 5592604788Blåhakevägen 16 BHospital activities · NACE 8610Est. 20202 employees
Revenue 2025
SEK 10M
+35% vs 2024
EBITDA margin
44.8%
+106% vs 2024
Equity ratio
58.9%
Financial strength
Net profit 2025
SEK 2,7M
+102% vs 2024
| Revenue | SEK 10M | +35% |
| EBITDA | SEK 4,5M | +106% |
| Net profit | SEK 2,7M | +102% |
| Total assets | SEK 8,2M | +89% |
| Equity | SEK 4,8M | +79% |
| Employees | 2 | — |
Legal name
Bromma neurofys AB
Org number
5592604788
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
23 juni 2020
Share capital
SEK 25 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-05-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Aktiebolaget ska främst arbeta inom neurofysiologisk diagnostik inom hälso- och sjukvård. I mindre utsträckning hålla föredrag inom neurofysiologi och andra medicinska områden.
Address
Blåhakevägen 16 B
Email
admin@brommaneurofys.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 130 | 2 939 | 3 309 | 7 370 | 9 952 |
| Staff expenses | — | — | −1 302 | −2 345 | — |
| EBITDA | 571 | 978 | 942 | 2 166 | 4 454 |
| Depreciation & amort. | −0 | −0 | — | — | −0 |
| EBIT | 571 | 978 | 942 | 2 166 | 4 454 |
| Net financials | — | −98 | 10 | 60 | 87 |
| Profit before tax | 570 | 929 | 952 | 1 670 | 3 396 |
| Tax | −122 | −200 | −197 | −341 | −708 |
| Net profit | 448 | 729 | 755 | 1 329 | 2 688 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 926 | 1 849 | 2 588 | 4 327 | 8 160 |
| Equity | 493 | 1 222 | 1 734 | 2 692 | 4 809 |
| Long-term debt | 0 | 0 | — | — | 0 |
| Short-term debt | 432 | 627 | 854 | 1 078 | 1 650 |
| Total debt | 432 | 627 | 854 | 1 078 | 1 650 |
EBITDA margin
44.8%
This company
15.8%
Market median
+184% vs market
20212025
Equity ratio
58.9%
This company
38.2%
Market median
+54% vs market
20212025
Return on equity
55.9%
This company
18.4%
Market median
+204% vs market
20212025
Net profit margin
27.0%
This company
8.1%
Market median
+233% vs market
20212025
Asset turnover
1.22×
This company
1.12×
Market median
+9% vs market
20212025
Debt / equity
0.70×
This company
0.62×
Market median
+13% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-06-01 – 2025-05-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-06-01 – 2024-05-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-06-01 – 2023-05-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-06-01 – 2022-05-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-06-01 – 2021-05-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PM Audit | Audit | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bromma neurofys AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Mikael Ringaby | Audit | 0 companies |
| Lars Johan Widenfalk | Chairman | 0 companies |
| Nils Georg Widenfalk | Deputy Board Member | 0 companies |
| Anna Britta Ida Frick | Board of Directors | 0 companies |